What is Sensorion?
Founded in 2009 and headquartered in Montpellier, France, Sensorion is a specialized biotechnology company dedicated to the restoration, treatment, and prevention of hearing loss disorders. By focusing on the underlying biological mechanisms of auditory impairment, the firm has established a robust portfolio of therapeutic candidates. Its market position is defined by its commitment to scientific rigor and its ability to navigate the complex regulatory landscape of clinical-stage drug development. As a pioneer in the field, Sensorion leverages its deep expertise in inner ear biology to create transformative solutions for patients suffering from various forms of hearing impairment, ranging from genetic conditions to acquired sensory loss.
How much funding has Sensorion raised?
Sensorion has raised a total of $64.8M across 2 funding rounds:
Grant
$10.4M
Other Financing Round
$54.4M
Grant (2019): $10.4M with participation from Hospital Research-University
Other Financing Round (2024): $54.4M led by Sofinnova Partners, Invus, and Redmile Group
Key Investors in Sensorion
Sofinnova Partners
A leading European venture capital firm specialized in Life Sciences that invests across the value chain from early-stage opportunities to late-stage companies.
Invus
An investment firm founded in 1985, providing financial advice and strategic investment services with a focus on long-term value creation.
Redmile Group
A New York-based firm operating within the Venture Capital and Private Equity industry, known for its focus on high-growth healthcare and life sciences ventures.
What's next for Sensorion?
With the recent strategic investment, Sensorion is well-positioned to accelerate its clinical development programs and expand its research capabilities. The company's strategic roadmap involves scaling its therapeutic pipeline and strengthening its operational infrastructure to support late-stage clinical trials. By prioritizing the advancement of its lead candidates, Sensorion aims to achieve key regulatory milestones that will validate its technology on a global scale. The continued support from high-profile life sciences investors suggests a long-term commitment to the firm's mission, providing the necessary resources to navigate the high-stakes environment of biotech innovation and ultimately bring life-changing treatments to market.
See full Sensorion company page
